🚨 New peer-reviewed evidence linking mRNA COVID-19 vaccines to cancer recurrence and increased incidence raises urgent questions.
A case from Kochi Medical School, Japan, published in the Journal of Dermatological Science, details an 85-year-old woman in remission from breast cancer for over a year.
One month after her sixth mRNA vaccine dose in early 2023, she developed aggressive metastatic skin lesions.
Biopsies confirmed invasive ductal carcinoma with high mitotic activity.
Immunohistochemistry revealed SARS-CoV-2 spike protein in nearly all tumor cells’ cytoplasm and nuclei—a novel finding.
No nucleocapsid protein was detected, confirming the vaccine as the spike source, not a natural infection.
Professor Shigetoshi Sano, the lead author, stated, “The presence of spike protein but not nucleocapsid protein in cancer cells is a novel finding… strongly suggesting a potential link between mRNA vaccines and cancer progression/metastasis.”
The study proposes several mechanisms for this link.
Vaccine mRNA or plasmid DNA could integrate into host DNA, disrupting tumor suppressor genes like TP53.
Spike protein may upregulate PD-L1, suppressing immune responses, and inhibit Type I interferons, weakening anti-tumor defenses.
It may also activate estrogen receptors, potentially fueling hormone-sensitive cancers like breast and ovarian.
Large-scale epidemiological data amplify these concerns.
A 2024 South Korean study in Biomarker Research, analyzing 8.4 million adults, found a 27% higher cancer incidence in vaccinated versus unvaccinated groups (HR 1.27, 95% CI: 1.21–1.33) within one year.
Specific increases included:
• Prostate: 69% (HR 1.69, 95% CI: 1.35–2.11)
• Lung: 53% (HR 1.53, 95% CI: 1.25–1.87)
• Thyroid: 35% (HR 1.35, 95% CI: 1.21–1.51)
• Gastric: 34% (HR 1.34, 95% CI: 1.13–1.58)
• Colorectal: 28% (HR 1.28, 95% CI: 1.12–1.47)
• Breast: 20% (HR 1.20, 95% CI: 1.07–1.34)
mRNA vaccines showed a 20% risk increase (HR 1.20, 95% CI: 1.14–1.26), with stronger signals for breast, colorectal, lung, and thyroid cancers.
Booster doses heightened risks, notably for pancreatic (125%, HR 2.25, p<0.001) and gastric (23%, HR 1.23, p=0.041) cancers.
Women and those over 75 faced the highest absolute risks, while younger adults (<65) showed elevated relative risks for thyroid and breast cancers.
An Italian cohort study of approximately 300,000 people over 30 months found similar trends.
Breast, bladder, and colorectal cancers rose 6–30 months post-vaccination, with risks increasing by dose number.
Epidemiologist Nicolas Hulscher called the data “striking,” urging immediate regulatory review.
The evidence—spike protein in cancer cells and population-wide cancer surges—continues to mount, demonstrating that mRNA COVID-19 vaccines are not safe and raising urgent concerns about regulatory oversight and transparency.
